Twist Bioscience Corporation announced preliminary, unaudited revenue for the first quarter of fiscal 2026.
Total revenue for the first quarter of fiscal 2026 grew 17% to approximately $103.7 million compared to the same period of fiscal 2025.
Key revenue growth areas included DNA Synthesis and Protein Solutions, as well as NGS Applications exceeding guidance expectations.
Total Revenue Growth
Total revenue grew 17% to approximately $103.7 million in the first quarter of fiscal 2026 compared to the same period in fiscal 2025.
DNA Synthesis and Protein Solutions
Revenue from this segment grew by 27% to approximately $51.1 million in the first quarter of fiscal 2026.
NGS Applications Performance
Revenue from NGS Applications reached approximately $52.6 million in the first quarter of fiscal 2026, ahead of guidance expectations.
- The company's robust revenue growth of 17% indicates a strong start to fiscal year 2026.
- The performance of key segments, such as DNA Synthesis and Protein Solutions, demonstrates promising growth potential for Twist Bioscience.
- Exceeding NGS Applications revenue expectations reflects positive customer demand and operational efficiency.
Twist Bioscience's preliminary revenue results for the first quarter of fiscal 2026 showcase a solid performance with double-digit growth in key revenue areas.